Search

Sanofi SA

Closed

SectorHealthcare

81.04 0.07

Overview

Share price change

24h

Current

Min

80.98

Max

81.19

Key metrics

By Trading Economics

Income

3.9B

5.8B

Sales

11B

21B

P/E

Sector Avg

15.922

34.393

EPS

1.59

Dividend yield

4.88

Profit margin

27.234

Employees

82,878

EBITDA

2.2B

2.8B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+33.26% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.88%

2.54%

Next Earnings

24 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-4.1B

100B

Previous open

80.97

Previous close

81.04

News Sentiment

By Acuity

34%

66%

90 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2025, 10:06 UTC

Major Market Movers

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 Jul 2025, 06:00 UTC

Earnings

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30 Jul 2025, 10:20 UTC

Earnings

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30 Jul 2025, 05:31 UTC

Earnings

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

6 Aug 2025, 05:02 UTC

Acquisitions, Mergers, Takeovers

Sanofi Completes the Acquisition of Vigil Neuroscience

6 Aug 2025, 05:00 UTC

Acquisitions, Mergers, Takeovers

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 Aug 2025, 13:16 UTC

Earnings

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 Aug 2025, 12:40 UTC

Earnings

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 Jul 2025, 08:15 UTC

Market Talk
Earnings

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 Jul 2025, 05:56 UTC

Market Talk
Earnings

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 Jul 2025, 05:30 UTC

Earnings

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 Jul 2025, 05:30 UTC

Earnings

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 Jul 2025, 05:30 UTC

Earnings

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 Jul 2025, 05:30 UTC

Earnings

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 Jul 2025, 05:30 UTC

Earnings

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 Jul 2025, 05:30 UTC

Earnings

Sanofi 2Q Business Operating Profit EUR2.46B

31 Jul 2025, 05:30 UTC

Earnings

Sanofi 2Q Adj EPS EUR1.59

31 Jul 2025, 05:30 UTC

Earnings

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 Jul 2025, 05:30 UTC

Earnings

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 Jul 2025, 05:30 UTC

Earnings

Sanofi 2Q Net Pft EUR3.94B

31 Jul 2025, 05:30 UTC

Earnings

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 Jul 2025, 05:30 UTC

Earnings

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 Jul 2025, 05:30 UTC

Earnings

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 Jul 2025, 05:30 UTC

Earnings

Sanofi 2Q Sales EUR9.99B

31 Jul 2025, 05:30 UTC

Earnings

Sanofi Backs 2025 EPS Adj View

31 Jul 2025, 05:30 UTC

Earnings

Sanofi Narrows 2025 Sales View

31 Jul 2025, 05:30 UTC

Earnings

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30 Jul 2025, 07:48 UTC

Market Talk
Earnings

Santander Results Get Lukewarm Reaction -- Market Talk

30 Jul 2025, 06:41 UTC

Market Talk
Earnings

Santander's Strategic Investments in Focus -- Market Talk

30 Jul 2025, 04:52 UTC

Earnings

Santander End-2Q CET1 Ratio 13%

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

33.26% upside

12 Months Forecast

Average 107.845 EUR  33.26%

High 124 EUR

Low 90 EUR

Based on 14 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

10

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

91.3 / 96.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

90 / 374 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.